PDF document = Adobe Acrobat required to view this document.

Get Acrobat Reader, click here Get Acrobat here »

THE ONCOLOGISTS PAGE

Posted on Sat, July 9, 2005

Up-Regulation of EphB4 in Mesotheloma and Its Biological Significance

Dr. Parkash S. Gill --
USC Norris Comprehensive Cancer Center
www.aacrjournals.org
Clin Cancer Res 2005;11(12) June 15, 2005
Pg. 4305

Read the full article

Posted on Tue, August 31, 2004

Killswitch

Lori Oliwenstien --
USC Health Magazine

In addition to blocking an enzyme responsible for tumor growth and metastasis, the drug VEGLIN appears to slow the growth of the cancer cells themselves. The success of Dr. Alexandra M. Levine, M.D. distinguished Professor of Medicine, chief of hematology at the Keck School of Medicine and the medical director of the USC/Norris Cancer Hospital has treated 37 patients with various types of cancers with the Veglin. "... the results are quite impressive, and we are very pleased so far".

Read the full article

Eligibility Criteria for Veglin

Criteria before a patient can have Veglin per FDA protocol developed

As a professional Oncologist, you will find here some of Dr. Gill's recent technical writing that causes us all to have a great hope.

TECHNICAL DOCUMENT (revision - July 2004):
A Phase II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin) in the Treatment of Relapsed Malignant Mesothelioma

Top of Page